Terapevticheskii arkhiv

Терапевтический архив

0040-36602309-5342

LLC Obyedinennaya Redaktsiya

31937

Editorial article

Передовая статья

Review Article

Successes and unsolved problems in the study of celiac disease

Успехи и нерешенные проблемы в изучении целиакии

Osipenko

M F

Осипенко

М Ф

Shrainer

E V

Шрайнер

Е В

Parfenov

A I

Парфенов

А И

«Новосибирский государственный медицинский университет» Минздрава России

Институт химической биологии и фундаментальной медицины СО РАН

«Московский клинический научно-практический центр» Департамента здравоохранения Москвы

15022016

882

VOL 88, NO2 ()

ТОМ 88, №2 (2016)

9710010042020

2016

Consilium Medicum

ООО "Консилиум Медикум"

https://creativecommons.org/licenses/by-nc-sa/4.0

https://ter-arkhiv.ru/0040-3660/article/view/31937

The review gives current views on the problem of celiac disease (gluten enteropathy). It presents the pathogenetic components of pathology development, associations with the specific features of the microflora in different parts of the gastrointestinal tract, as well as groups at risk for this pathology. The idea on other types of gluten intolerance is briefly given. Current elaborated approaches to gluten enteropathy therapy are provided.

Аннотация В обзоре даны современные взгляды на проблему целиакии (глютеновой энтеропатии). Представлены патогенетические звенья развития патологии, ассоциации с особенностями микрофлоры различных отделов желудочно-кишечного тракта, приведены группы риска формирования данной патологии. Коротко дано представление о других вариантах непереносимости глютена. Приведены современные разрабатываемые подходы к терапии глютеновой энтеропатии.

celiac diseasegluten enteropathygluten intolerancegliadinzonulintransglutaminaseendomysium

целиакияглютеновая энтеропатиянепереносимость глютенаглиадинзонулинтрансглутаминазаэндомизий

Sapone A, Bai JC, Ciacci C, Dolinsek J et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classication. BMC Med. 2012;10:13. doi:10.1186/1741-7015-10-13.

McAllister CS, Kagnoff MF. The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. Semin Immunopathol. 2012;34:581-600. doi:10.10071900281-012-0318-8.

Drago S, El Asmar R, Di Pierro M et al. Gliadin, zonulin and permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. 2006;41:408-419. doi:10.1080/00365520500235334.

Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity and cancer. Physiol Rev. 2011;91:151-175. doi:10.1152/physrev.00003.2008.

McAllister CS, Kagnoff MF. The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. Semin Immunopathol. 2012;34:581-600. doi:10.10071900281-012-0318-8.

Odii BO, Coussons P. Biological functionalities of transglutaminase and the possibility of its compensation by other members of transglutaminase family. Scientific World J. 2014;2014. ID 714561. doi:10.1155/2014/714561.

Matysiak-Budnik T, Moura IC, Arcos-Fajardo M et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in CD. J. Cell Biol. 2008;180(1):i1-i1. doi:10.1083/jcb1801oia1.

Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nature Clin Pract Gastroenterol Hepatol. 2005;2(39):416-422. doi:10.1038/ncpgasthep0259.

Сабельникова Е.А., Парфенов А.И., Крумс Л.М., Гудкова Р.Б, Сагынбаева В.Э., Быкова С.В. Значение метода определения деамидированного пептида глиадина в диагностике целиакии. Терапевтический архив. 2014;86(2):39-43.

10.

Schumann M, Richter JF, Wedell I et al. Mechanisms of epithelial translocation of the alpha — gliadin-33mer in coeliac sprue. Gut. 2008;57:747-754. doi:10.1136/gut.2007.136366.

11.

Sellitto M, Bai G, Serena G et al. Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. PloS ONE. 2012;7(3). doi:10.1371/journal.pone.0033387.

12.

Palmer C, Bik E, DiGiulio D, Relman D, Brown P. Development of the Human Infant Intestinal Microbiota. Plos Biol. 2007;5(7):e177. doi:10.1371/journal.pbio.0050177.

13.

Miyara M, Sakaguchi S. Human FoxP3+CD4+ regulatory T cells: their knowns and unknowns. Immunol Cell Biol. 2011;89(3):346-351. doi:10.1038/icb.2010.137.

14.

Forsberg G, Fahlgren A, Horstedt P, Hammarstrom S, Hernell O, Hammarstrom M. Presence of Bacteria and Innate Immunity of Intestinal Epithelium in Childhood Celiac Disease. Am J Gastroenterol. 2004;99(5):894-904. doi:10.1111/j.1572-0241.2004.04157.x.

15.

Nadal I, Donant E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol. 2007;56(12):1669-1674. doi:10.1099/jmm.0.47410-0.

16.

Sánchez E, Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Reduced diversity and increased virulence-gene carriage in intestinal enterobacteria of coeliac children. BMC Gastroenterol. 2008;8(1):50. doi:10.1186/1471-230x-8-50.

17.

Collado M, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiol. 2008;8(1):232. doi:10.1186/1471-2180-8-232.

18.

Sanz Y, Sánchez E, Marzotto M, Calabuig M, Torriani S, Dellaglio F. Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. FEMS Immunol Med Microbiol. 2007;51(3):562-568. doi:10.1111/j.1574-695x.2007.00337.x.

19.

Rostami Nejad M, Rostami K, Yamaoka Y, Mashayekhi R, Molaei M, Dabiri H, Al Dulaimi D, Mirsattari D, Zojaji H, Norouzinia M, Zali MR. Clinical and histological presentation of Helicobacter pylori and gluten related gastroenteropathy. Arch Iran Med. 2011;14:115-118. doi:011142/aim.009.

20.

Васильев Ю.В., Парфенов Д.А. Особенности хронического гастрита при глютеновой энтеропатии. Российский гастроэнтерологический журнал. 1995;2:37-41.

21.

Rostami-Nejad M, Villanacci V, Mashayakhi R et al. Celiac disease and Hp infection association in Iran. Rev Espenferm Dig. 2009;101(12). doi:10.4321/s1130-01082009001200004.

22.

Ciacci C, Squillante A, Rendina D et al. Helicobacter pylori infection and peptic disease in coeliac disease. Eur J Gastroenterol Hepatol. 2000;12(12):1283-1287. doi:10.1097/00042737-200012120-00004.

23.

Diamanti A, Maino C, Niveloni S et al. Characterization of gastric mucosal lesions in patients with celiac disease: a prospective controlled study. Am J Gastroenterol. 1999;94(5):1313-1319. doi:10.1111/j.1572-0241.1999.01082.x.

24.

Aydogdu S, Cakir M, Ali Yuksekkaya H et al. Helicobacter pylori infection in children with celiac disease. Scand J Gastroenterol. 2008;43(9):1088-1093. doi:10.1080/00365520802101846.

25.

Luzza F, Mancuso M, Imeneo M et al. Helicobacter pylori Infection in Children with Celiac Disease: Prevalence and Clinicopathologic Features. J Pediat Gastroenterol Nutr. 1999;28(2): 143-146. doi:10.1097/00005176-199902000-00009.

26.

Crabtree J, O’Mahony S, Wyatt J et al. Helicobacter pylori serology in patients with coeliac disease and dermatitis herpetiformis. J Clin Pathol. 1992;45(7):597-600. doi:10.1136/jcp.45.7.597.

27.

Konturek P, Karczewska E, Dieterich W, Hahn E, Schuppan D. Increased prevalence of Helicobacter pylori infection in patients with celiac disease. Am J Gastroenterol. 2000;95(12):3682-3683. doi:10.1111/j.1572-0241.2000.03421.x.

28.

Chen Y. Inverse Associations of Helicobacter pylori With Asthma and Allergy. Arch Intern Med. 2007;167(8):821. doi:10.1001/archinte.167.8.821.

29.

Arnold I, Dehzad N, Reuter S et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Investigat. 2011;121(8):3088-3093. doi:10.1172/jci45041.

30.

Chen Y, Segers S, Blaser M. Association between Helicobacter pylori and mortality in the NHANES III study. Gut. 2013;62(9):1262-1269. doi:10.1136/gutjnl-2012-303018.

31.

Catassi C, Kryszak D, Bhatti B et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42(7):530-538. doi:10.3109/07853890.2010.514285.

32.

Ludvigsson J, Leffler D, Bai J et al. The Oslo definitions for coeliac disease and related terms. Gut. 2012;62(1):43-52. doi:10.1136/gutjnl-2011-301346.

33.

Парфенов А.И. Новые горизонты изучения чувствительности к глютену. Терапевтический архив. 2013;85(2):4-7.

34.

Ludvigsson J, Card T, Kaukinen K et al. Screening for celiac disease in the general population and in high-risk groups. United Eur Gastroenterol J. 2014;3(2):106-120. doi:10.1177/2050640614561668.

35.

Catassi C, Bai J, Bonaz B et al. Non-Celiac Gluten Sensitivity: The New Frontier of Gluten Related Disorders. Nutrients. 2013;5(10):3839-3853. doi:10.3390/nu5103839.

36.

Carroccio A, Mansueto P, Iacono G et al. Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity. Am J Gastroenterol. 2012;107(12):1898-1906. doi:10.1038/ajg.2012.236.

37.

Biesiekierski J, Newnham E, Shepherd S, Muir J, Gibson P. Characterization of Adults With a Self-Diagnosis of Nonceliac Gluten Sensitivity. Nutrit Clin Pract. 2014;29(4):504-509. doi:10.1177/0884533614529163.

38.

Biesiekierski J, Iven J. Non-coeliac gluten sensitivity: piecing the puzzle together. United Eur Gastroenterol J. 2015;3(2):160-165. doi:10.1177/2050640615578388.

39.

Pinier M, Fuhrmann G, Verdu E, Leroux J. Prevention Measures and Exploratory Pharmacological Treatments of Celiac Disease. Am J Gastroenterol. 2010;105(12):2551-2561. doi:10.1038/ajg.2010.372.

40.

Wieser H, Koehler P. Detoxification of Gluten by Means of Enzymatic Treatment. J AOAC Int. 2012;95(2):356-363. doi:10.5740/jaoacint.sge_wieser.

41.

Leffler D, Kelly C, Abdallah H et al. A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge. Am J Gastroenterol. 2012;107(10):1554-1562. doi:10.1038/ajg.2012.211.

42.

Galipeau H, Wiepjes M, Motta J et al. Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders. Am J Gastroenterol. 2014;109(5):748-756. doi:10.1038/ajg.2014.48.

43.

44.

Galipeau H, Wiepjes M, Motta J et al. Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders. The American Journal of Gastroenterology. 2014;109(5):748-756. doi:10.1038/ajg.2014.48.

45.

Сабельникова Е.А., Крумс Л.М., Парфенов А.И., Воробьева Н.Н., Гудкова Р.Б. Особенности реабилитации больных глютенчувствительной целиакией. Терапевтический архив. 2013;85(1):103-107.

46.

Croese J, Gaze S, Loukas A. Changed gluten immunity in celiac disease by Necatoramericanus provides new insights into autoimmunity. Int J Parasitol. 2013;43(3-4):275-282. doi:10.1016/j.ijpara.2012.12.005.

47.

Sollid L, Khosla C. Novel therapies for coeliac disease. J Int Med. 2011;269(6):604-613. doi:10.1111/j.1365-2796.2011.02376.x.

48.

A Phase II Study of CCX282-B in Patients With Celiac Disease — Full Text View — ClinicalTrials.govhttp://clinicaltrials.gov/ct2/show/NCT00540657 Access date 20.06.2015

49.

ImmusanThttp://www.immusant.com/ Access date: 20.06.2015